Prostate cancer (PCa) is the most commonly diagnosed malignant neoplasm in men in the
Western world. Localized low-risk PCa has an excellent prognosis thanks to effective local …

Simple Summary Prostate cancer (PCa) is characterized by various genomic alterations that
play a pivotal role in carcinogenesis. Efforts in precision medicine aimed at improving …

The prognosis and overall survival of castration-resistant prostate cancer (CRPC) patients
are poor. The search for novel and efficient anti-CRPC agents is therefore extremely …

The term “cistrome” refers to the genome-wide location of regulatory elements associated
with transcription factor binding-sites. The cistrome of key regulatory factors in prostate …

Resistance to the current Androgen Receptor Signaling Inhibitor (ARSI) therapies has led to
higher incidences of therapy-induced neuroendocrine-like prostate cancer (t-NEPC). This …

Background Oncologic outcomes for patients with localized prostate cancer (PCa)
undergoing radical prostatectomy (RP) can vary widely. Hypermethylation of tumor …

Enzalutamide is a potent second-generation antiandrogen commonly used to treat hormone-
sensitive and castration-resistant prostate cancer (CRPC) patients. While initially effective …

A multitude of epigenetic modifications and genetic mutations have been found to play
pivotal roles in the development and progression of prostate cancer (PCa). The review …

Preclinical studies indicate that the epigenome is a potential target in prostate cancer, and
clinical trials are testing multiple agents that target the epigenome in different ways …

Prostate cancer is a multifactorial disease influenced by various molecular features. Over the
past decades, epigenetics, which is the study of changes in gene expression without altering …